Literature DB >> 18042322

Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects.

Adam P Klausner1, William D Steers.   

Abstract

Antimuscarinic drugs commonly used to treat overactive bladder are often associated with central nervous system (CNS) side effects including cognitive dysfunction, memory impairment, dizziness, fatigue, and headache. New agents show reduced CNS penetrance and better selectivity for the M3 muscarinic receptor. However, changes associated with aging may lead to alterations in blood-brain barrier permeability. Therefore, use of antimuscarinics in the elderly or in patients with Alzheimer's disease presents a significant challenge. This review highlights muscarinic receptor distribution and function in the CNS, provides a description and incidence of CNS side effects with therapy, offers information specific to currently available agents, and describes the use of antimuscarinics in special populations including children, the elderly, and patients with Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18042322     DOI： 10.1007/s11934-007-0046-0

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  38 in total

1.  Transient memory impairment and hallucinations associated with tolterodine use.

Authors:  Jack W Tsao; Kenneth M Heilman
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

2.  Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs.

Authors:  Elaine K Perry; Linda Kilford; Andrew J Lees; David J Burn; Robert H Perry
Journal:  Ann Neurol       Date:  2003-08       Impact factor: 10.422

3.  Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.

Authors:  Roger R Dmochowski; Victor Nitti; David Staskin; Karl Luber; Rodney Appell; G Willy Davila
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

4.  Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).

Authors:  Alan D Garely; Joel M Kaufman; Peter K Sand; Neila Smith; Masakazu Andoh
Journal:  Clin Ther       Date:  2006-11       Impact factor: 3.393

5.  M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.

Authors:  Ken Ikeda; Seiji Kobayashi; Mami Suzuki; Keiji Miyata; Makoto Takeuchi; Toshimitsu Yamada; Kazuo Honda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-06-14       Impact factor: 3.000

6.  Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?

Authors:  Adam P Klausner; Seema Sharma; Sophie Fletcher; Pamela Neff; Sang-Kuk Yang; Hwancheol Son; Jeremy B Tuttle; William D Steers
Journal:  J Urol       Date:  2008-03       Impact factor: 7.450

7.  Disruption of the blood-brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of Gulf-War syndrome.

Authors:  Ali Abdel-Rahman; Ashok K Shetty; Mohamed B Abou-Donia
Journal:  Neurobiol Dis       Date:  2002-08       Impact factor: 5.996

8.  The impact on health-related quality of life of stress, urge and mixed urinary incontinence.

Authors:  K S Coyne; Z Zhou; C Thompson; E Versi
Journal:  BJU Int       Date:  2003-11       Impact factor: 5.588

Review 9.  Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.

Authors:  F Haab; L Stewart; P Dwyer
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096

10.  Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.

Authors:  L Cardozo; M Lisec; R Millard; O van Vierssen Trip; I Kuzmin; T E Drogendijk; M Huang; A M Ridder
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450
View more
  6 in total

1.  Imidafenacin has no influence on learning in nucleus basalis of Meynert-lesioned rats.

Authors:  Takanobu Yamazaki; Ayako Fukata
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-08-31       Impact factor: 3.000

Review 2.  Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.

Authors:  Michael B Chancellor; David R Staskin; Gary G Kay; Bobby W Sandage; Michael G Oefelein; Jack W Tsao
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

Review 3.  Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.

Authors:  Karin Glavind; Michael Chancellor
Journal:  Int Urogynecol J       Date:  2011-04-06       Impact factor: 2.894

4.  Brain penetration of the OAB drug trospium chloride is not increased in aged mice.

Authors:  Jasmin Kranz; Ernst Petzinger; Joachim Geyer
Journal:  World J Urol       Date:  2011-11-27       Impact factor: 4.226

5.  The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome.

Authors:  Full-Young Chang; Ching-Liang Lu; Jiing-Chyuan Luo; Tseng-Shing Chen; Mei-Jung Chen; Hsiu-Ju Chang
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

6.  An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents.

Authors:  Daniela C Moga; Qishan Wu; Pratik Doshi; Amie J Goodin
Journal:  BMC Geriatr       Date:  2017-12-28       Impact factor: 3.921
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.